University of Texas Southwestern Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

2013

  1. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3763-3772